FDA Adds Warning Label To Obesity Drugs For Eye Condition
NDTV

The US FDA is requiring obesity and diabetes drugs like Wegovy and Ozempic to carry warning labels for a rare eye condition.
The US Food and Drug Administration has mandated that popular GLP-1 medications, including Novo Nordisk's Wegovy and Ozempic alongside Eli Lilly's Mounjaro, Zepbound, and Foundayo, must include new warnings. These labels will caution patients that the drugs may potentially increase the risk of developing non-arteritic anterior ischemic optic neuropathy, also known as NAION, a serious eye condition. This regulatory update affects major players in the pharmaceutical market for weight loss and diabetes treatments.
Why it matters: The new FDA warning informs patients and healthcare providers of a potential increased risk of a serious eye condition associated with widely used obesity and diabetes medications.

